Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis

References

• Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009;60:1024–1031.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Christophers E, Barker JN, Chalmers RJ, Chimenti S, Krueger GG, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol. 2007;156:258–262.
   PubMed Web of Science ®Google Scholar
• Kragballe K. Management of difficult to treat locations of psoriasis. Scalp, face, flexures, palm/soles and nails. Curr Probl Dermatol. 2009;38:160–171.
   PubMedGoogle Scholar
• Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003;49:271–275.
   PubMed Web of Science ®Google Scholar
• Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148:1–18.
   PubMedGoogle Scholar
• Kumar B, Saraswat A, Kaur I. Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Derm Venereol. 2002;82:192–195.
   PubMed Web of Science ®Google Scholar
• Ammoury A, El Sayed F, Dhaybi R, Bazex J. Palmoplantar pustulosis should not be considered as a variant of psoriasis. J Eur Acad Dermatol Venereol. 2008;22:392–393.
   PubMedGoogle Scholar
• Bulai Livideanu C, Lahfa M, Mazereeuw-Hautier J, Paul C. Efficacy of ustekinumab in palmoplantar psoriasis. Dermatology. 2010;221:321–323.
   PubMed Web of Science ®Google Scholar
• Lior S, Grigory K, Pnina S, Joseph S, Felix P. Therapeutic hotline. Alefacept in the treatment of hyperkeratotic palmoplantar psoriasis. Dermatol Ther. 2010;23:556–560.
   PubMedGoogle Scholar
• Adisen E, Tekin O, Gulekon A, Gurer MA. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol. 2009;23:814–819.
   PubMed Web of Science ®Google Scholar
• Mehta BH, Amladi ST. Evaluation of topical 0.1% tazarotene cream in the treatment of palmoplantar psoriasis: an observer-blinded randomized controlled study. Indian J Dermatol. 2011;56:40–43.
   PubMedGoogle Scholar
• Kumar B, Kumar R, Kaur I. Coal tar therapy in palmoplantar psoriasis: old wine in an old bottle? Int J Dermatol. 1997;36:309–312.
   PubMedGoogle Scholar
• Egawa K. Topical vitamin D3 derivatives in treating hyperkeratotic palmoplantar eczema: a report of five patients. J Dermatol. 2005;32:381–386.
   PubMedGoogle Scholar
• Nordal EJ, Christensen OB. Treatment of chronic hand dermatoses with UVB-TL01. Acta Derm Venereol. 2004;84:302–304.
   PubMedGoogle Scholar
• Behrens S, von Kobyletzki G, Gruss C, Reuther T, Altmeyer P, Kerscher M. PUVA-bath photochemotherapy (PUVA-soak therapy) of recalcitrant dermatoses of the palms and soles. Photodermatol Photoimmunol Photomed. 1999;15:47–51.
   PubMedGoogle Scholar
• Sezer E, Erbil AH, Kurumlu Z, Tastan HB, Etikan I. Comparison of the efficacy of local narrowband ultraviolet B (NB-UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. J Dermatol. 2007;34:435–440.
   PubMed Web of Science ®Google Scholar
• Neumann NJ, Mahnke N, Korpusik D, Stege H, Ruzicka T. Treatment of palmoplantar psoriasis with monochromatic excimer light (308-nm) versus cream PUVA. Acta Derm Venereol. 2006;86:22–24.
   PubMed Web of Science ®Google Scholar
• Ahmad K, Rogers S. Three years' experience with infliximab in recalcitrant psoriasis. Clin Exp Dermatol. 2006;31:630–633.
   PubMed Web of Science ®Google Scholar
• Yawalkar N, Hunger RE. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab. Dermatology. 2009;218:79–83.
   PubMed Web of Science ®Google Scholar
• Ghate JV, Alspaugh CD. Adalimumab in the management of palmoplantar psoriasis. J Drugs Dermatol. 2009;8:1136–1139.
   PubMedGoogle Scholar
• Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol. 2006;33:1447–1451.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Poulin Y, Bolduc C, Maari C, Provost N, Syrotuik J, Poulin-Costello CM, Nisen S, et al. Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol. 2008;7:940–946.
   PubMedGoogle Scholar
• Floristan U, Feltes R, Ramirez P, Alonso ML, De Lucas R. Recalcitrant palmoplantar pustular psoriasis treated with etanercept. Pediatr Dermatol. 2011;28:349–350.
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Salvini C, Massone C. Efalizumab for severe palmo-plantar psoriasis: an open-label pilot trial in five patients. J Eur Acad Dermatol Venereol. 2009;23:415–419.
   PubMedGoogle Scholar
• Myers W, Christiansen L, Gottlieb AB. Treatment of palmoplantar psoriasis with intramuscular alefacept. J Am Acad Dermatol. 2005;53:S127–S129.
   PubMed Web of Science ®Google Scholar
• Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20:100–108.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633–640.
   PubMed Web of Science ®Google Scholar
• Lillis JV, Guo CS, Lee JJ, Blauvelt A. Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis. Arch Dermatol. 2010;146:918–919.
   PubMedGoogle Scholar
• Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–1674.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–1684.
   PubMed Web of Science ®Google Scholar
• Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol. 1968;80:771–793.
   PubMed Web of Science ®Google Scholar
• Baker H. Psoriasis–clinical features. Br Med J. 1971;3:231–233.
   PubMedGoogle Scholar
• de Waal AC, van de Kerkhof PC. Pustulosis palmoplantaris is a disease distinct from psoriasis. J Dermatolog Treat. 2011;22:102–105.
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Massone C. Can we really separate palmoplantar pustulosis from psoriasis? J Eur Acad Dermatol Venereol. 2010;24:619–621; author reply 21.
   PubMed Web of Science ®Google Scholar
• Eriksson MO, Hagforsen E, Lundin IP, Michaelsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol. 1998;138:390–398.
   PubMed Web of Science ®Google Scholar
• Akiyama T, Seishima M, Watanabe H, Nakatani A, Mori S, Kitajima Y. The relationships of onset and exacerbation of pustulosis palmaris et plantaris to smoking and focal infections. J Dermatol. 1995;22:930–934.
   PubMedGoogle Scholar
• Yamamoto T. Extra-palmoplantar lesions associated with palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2009;23:1227–1232.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Nishioka K. Severe extra-palmoplantar pustulation associated with palmoplantar pustulosis. J Dermatol. 2004;31:690–692.
   PubMedGoogle Scholar
• Burden AD, Kemmett D. The spectrum of nail involvement in palmoplantar pustulosis. Br J Dermatol. 1996;134:1079–1082.
   PubMedGoogle Scholar
• Asumalahti K, Ameen M, Suomela S, Hagforsen E, Michaelsson G, Evans J, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol. 2003;120:627–632.
   PubMed Web of Science ®Google Scholar
• Mossner R, Kingo K, Kleensang A, Kruger U, Konig IR, Silm H, Westphal GA, Reich K, et al. Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol. 2005;124:282–284.
   PubMed Web of Science ®Google Scholar
• Psoriasis. Textbook of dermatology. In Camp RDRBreathrnach SM. ed. Oxford: Blackwell Publishing, 1998. p 1589–1649.
   Google Scholar
• Chigira M, Maehara S, Nagase M, Ogimi T, Udagawa E. Sternocostoclavicular hyperostosis. A report of nineteen cases, with special reference to etiology and treatment. J Bone Joint Surg Am. 1986;68:103–112.
   PubMedGoogle Scholar
• Torii K, Furuhashi T, Saito C, Kato H, Nishioka A, Nishida E, Shintani Y, Morita A, et al. Increased peripheral Th17 in patients with pustulosis palmaris et plantaris. Arch Dermatol Res. 2011;303:441–444.
   PubMedGoogle Scholar
• Kingo K, Mossner R, Koks S, Ratsep R, Kruger U, Vasar E, Reich K, Silm H, et al. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol. 2007;156:646–652.
   PubMedGoogle Scholar
• Kragballe K, Larsen FG. A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to clobetasol cream in palmo-plantar pustulosis. Acta Derm Venereol. 1991;71:540–542.
   PubMed Web of Science ®Google Scholar
• Marsland AM, Chalmers RJ, Hollis S, Leonardi-Bee J, Griffiths CE. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev. 2006;CD001433.
   PubMedGoogle Scholar
• V'Lckova-Laskoska MT, Caca-Biljanovska NG, Laskoski DS, Kamberova SJ. Palmoplantar pustulosis treated with itraconazole: a single, active-arm pilot study. Dermatol Ther. 2009;22:85–89.
   PubMedGoogle Scholar
• Adisen E, Gurer MA. Therapeutic options for palmoplantar pustulosis. Clin Exp Dermatol. 2009;35:219–222.
   PubMedGoogle Scholar
• Bhushan M, Burden AD, McElhone K, James R, Vanhoutte FP, Griffiths CE. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2001;145:546–553.
   PubMed Web of Science ®Google Scholar
• Ono T, Jono M, Kito M, Tomoda T, Kageshita T, Egawa K, Kuriya N, et al. Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris. Acta Otolaryngol Suppl. 1983;401:12–16.
   PubMedGoogle Scholar
• Gerdes S, Franke J, Domm S, Mrowietz U. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol. 2010;163:1116–1118.
   PubMed Web of Science ®Google Scholar
• Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):10–16.
   PubMed Web of Science ®Google Scholar
• Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130:933–943.
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;141:185–191.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210:194–199.
   PubMed Web of Science ®Google Scholar
• McKenna KE, Stern RS. The outcomes movement and new measures of the severity of psoriasis. J Am Acad Dermatol. 1996;34:534–538.
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther. 1998;23:391–398.
   PubMed Web of Science ®Google Scholar